• BT474人乳腺癌细胞(STR鉴定正确)

    价 格💁🏽:¥1800

    期 货🕺🏽:现货(冻存管发2支)

    保藏中心🧓🏻:BTCC

    资源编号:BTCC-1023

    产地:中国

    套 餐🪓:

    T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

    详细资料说明书下载质检报告(COA)

    Cell line nameBT-474
    SynonymsBt-474; BT474
    AccessionBTCC-1023
    Resource Identification InitiativeTo cite this cell line use: BT-474 (BTCC-1023)
    CommentsPart of: AKT genetic alteration cell panel (ATCC TCP-1029).
    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
    Part of: COSMIC cell lines project.
    Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
    Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
    Part of: GrayJW breast cancer cell line panel.
    Part of: ICBP43 breast cancer cell line panel.
    Part of: KuDOS 95 cell line panel.
    Part of: MD Anderson Cell Lines Project.
    Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
    Population: Caucasian.
    Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); 45.8 hours (PubMed=24389870); ~60-80 hours (CLS=300131); ~100 hours (DSMZ=ACC-64); 92.49 hours (GrayJW panel).
    Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
    Omics: Array-based CGH.
    Omics: CNV analysis.
    Omics: Deep exome analysis.
    Omics: Deep phosphoproteome analysis.
    Omics: Deep proteome analysis.
    Omics: Deep quantitative proteome analysis.
    Omics: DNA methylation analysis.
    Omics: Genome sequenced.
    Omics: Glycoproteome analysis by proteomics.
    Omics: Metabolome analysis.
    Omics: miRNA expression profiling.
    Omics: Protein expression by reverse-phase protein arrays.
    Omics: shRNA library screening.
    Omics: SNP array analysis.
    Omics: Transcriptome analysis by microarray.
    Omics: Transcriptome analysis by RNAseq.
    Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).
    Derived from site: In situ; Breast; UBERON=UBERON_0000310.
    Sequence variations
    • Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (PubMed=26865974).
    • Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (PubMed=21247443; PubMed=26865974).
    • Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (PubMed=21247443; PubMed=26865974).
    • Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (PubMed=26865974).
    • Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (PubMed=21247443; PubMed=26865974).
    • Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
    • Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
    • Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (PubMed=26865974; ATCC; Cosmic-CLP; DepMap).
    • Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19593635; PubMed=26865974; Cosmic-CLP; DepMap).
    • Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=26865974; PubMed=28889351; ATCC; Cosmic-CLP; DepMap).
    HLA typingSource: PubMed=25960936
    Class I
    HLA-AA*29:02
    HLA-BB*07:02
    HLA-CC*07:02,16:01
    Class II
    HLA-DQDQB1*03:04,06:02
    HLA-DRDRB1*15:01,15:01

    Source: PubMed=26589293
    Class I
    HLA-AA*02:46,29:02
    HLA-BB*07:02,35:08
    HLA-CC*07:02,16:01
    Class II
    HLA-DQDQB1*03:02,06:02
    HLA-DRDRB1*04:05,15:01

    Source: CLS=300131
    Class I
    HLA-AA*01:01:01,05:02:01
    HLA-BB*07:02:01,20:03:01
    HLA-CC*07:02:01,16:01:01
    Class II
    HLA-DPDPB1*04:01:01G,05:01:01G
    HLA-DQDQA1*01:02:01,03:03:01

    DQB1*06:02:01
    HLA-DRDRB1*04:01,15:01
    Genome ancestrySource: PubMed=30894373

    Origin% genome


    African0.6
    Native American0
    East Asian, North2.47
    East Asian, South0
    South Asian0
    European, North70.19
    European, South26.74
    DiseaseInvasive breast carcinoma of no special type (NCIt: C4194)
    Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
    HierarchyChildren:



    CVCL_AQ07 (BT-474 Clone 5)CVCL_A4CL (BT-474 Ecadherin EmGFP)CVCL_AR96 (BT-474 EEI)
    CVCL_AR86 (BT-474 Tam1)CVCL_A4AK (BT-474 Tam2)CVCL_4Y08 (BT-474/CMV-Luc)
    CVCL_IP20 (BT-474c1)CVCL_YX79 (BT474 A3)CVCL_4V65 (BT474-5FU[r])
    CVCL_ZL46 (BT474-J4)CVCL_EI02 (BT474-LAPRa)CVCL_EI03 (BT474-LAPRb)
    CVCL_VL01 (BT474-LR)CVCL_A2GH (LR-BT474)
    Sex of cellFemale
    Age at sampling60Y
    CategoryCancer cell line
    STR profileSource(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; PubMed=28889351

    Markers:
    AmelogeninX
    CSF1PO10,11
    D2S133819
    D3S135817
    D5S81811,13
    D7S8209,12
    D8S117910,12
    D13S31711
    D16S5399,11
    D18S5113,18
    D19S43314,17
    D21S1128,32.2
    FGA22,25
    Penta D9,14
    Penta E5
    TH017
    TPOX8
    vWA15,16

    Run an STR similarity search on this cell line
    Web pageshttp://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=BT-474
    https://lincs.hms.harvard.edu/resources/reagents/icbp43/
    https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
    https://tcpaportal.org/mclp/
    Publications

    PubMed=212572; DOI=10.1093/jnci/61.4.967
    Lasfargues E.Y., Coutinho W.G., Redfield E.S.
    Isolation of two human tumor epithelial cell lines from solid breast carcinomas.
    J. Natl. Cancer Inst. 61:967-978(1978)

    PubMed=94035; DOI=10.1007/BF02618252
    Lasfargues E.Y., Coutinho W.G., Dion A.S.
    A human breast tumor cell line (BT-474) that supports mouse mammary tumonr virus replication.
    In Vitro 15:723-729(1979)

    DOI=10.1007/978-1-4757-0019-0_7
    Lasfargues E.Y., Coutinho W.G.
    Human breast tumor cells in culture; new concepts in mammary carcinogenesis.
    (In) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York (1981)

    PubMed=6582512; DOI=10.1073/pnas.81.2.568
    Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
    Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
    Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

    PubMed=1961733; DOI=10.1073/pnas.88.23.10657
    Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
    Mutations in p53 as potential molecular markers for human breast cancer.
    Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

    DOI=10.1016/B978-0-12-333530-2.50009-5
    Leibovitz A.
    Cell lines from human breast.
    (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

    PubMed=7842014; DOI=10.1038/ng1094-155
    Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.
    Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.
    Nat. Genet. 8:155-161(1994)

    PubMed=9671407; DOI=10.1038/sj.onc.1201814
    Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
    Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
    Oncogene 16:2865-2878(1998)

    PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::aid-gcc9>3.0.CO;2-B
    Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
    Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
    Genes Chromosomes Cancer 28:308-317(2000)

    PubMed=10969801
    Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
    Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
    Cancer Res. 60:4519-4525(2000)

    PubMed=11687795; DOI=10.1038/ng754
    Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
    Assembly of microarrays for genome-wide measurement of DNA copy number.
    Nat. Genet. 29:263-264(2001)

    PubMed=12353263; DOI=10.1002/gcc.10107
    Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
    Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
    Genes Chromosomes Cancer 35:204-218(2002)

    PubMed=12800145; DOI=10.1002/gcc.10218
    Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
    A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
    Genes Chromosomes Cancer 37:333-345(2003)

    PubMed=16142302; DOI=10.3892/ijo.27.4.881
    de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
    Molecular characterization of breast cancer cell lines by a low-density microarray.
    Int. J. Oncol. 27:881-892(2005)

    PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
    Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
    BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
    Cancer Res. 66:41-45(2006)

    PubMed=16195238; DOI=10.1093/carcin/bgi231
    Hussain-Hakimjee E.A., Peng X., Mehta R.R., Mehta R.G.
    Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
    Carcinogenesis 27:551-559(2006)

    PubMed=16417655; DOI=10.1186/bcr1370
    Shadeo A., Lam W.L.
    Comprehensive copy number profiles of breast cancer cell model genomes.
    Breast Cancer Res. 8:R9.1-R9.14(2006)

    PubMed=16541312; DOI=10.1007/s10549-006-9186-z
    Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
    Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
    Breast Cancer Res. Treat. 99:97-101(2006)

    PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
    Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
    A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell 10:515-527(2006)

    PubMed=17334996; DOI=10.1002/gcc.20438
    Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S., Ringner M., Hoglund M., Borg A.
    High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
    Genes Chromosomes Cancer 46:543-558(2007)

    PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004
    Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
    The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
    Mol. Oncol. 1:84-96(2007)

    PubMed=18386134; DOI=10.1007/s10585-008-9169-z
    Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
    Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
    Clin. Exp. Metastasis 25:549-557(2008)

    PubMed=19582160; DOI=10.1371/journal.pone.0006146
    Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
    Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    PLoS ONE 4:E6146-E6146(2009)

    PubMed=19671800; DOI=10.1158/0008-5472.CAN-08-4490
    Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.-M., Gilmer T.M.
    Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
    Cancer Res. 69:6871-6878(2009)

    PubMed=19727395; DOI=10.1371/journal.pone.0006888
    Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
    Systems-level modeling of cancer-fibroblast interaction.
    PLoS ONE 4:E6888-E6888(2009)

    CLPUB00423
    Morrison B.J.
    Breast cancer stem cells: tumourspheres and implications for therapy.
    Thesis PhD (2010), Griffith University, Australia

    PubMed=19593635; DOI=10.1007/s10549-009-0460-8
    Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
    Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
    Breast Cancer Res. Treat. 121:53-64(2010)

    PubMed=20070913; DOI=10.1186/1471-2407-10-15
    Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
    Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
    BMC Cancer 10:15.1-15.10(2010)

    PubMed=20164919; DOI=10.1038/nature08768
    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
    Signatures of mutation and selection in the cancer genome.
    Nature 463:893-898(2010)

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
    Cancer Res. 70:2158-2164(2010)

    PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6
    Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V., Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L., Kallioniemi O.-P.
    Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
    Genome Biol. 12:R6.1-R6.13(2011)

    PubMed=22460905; DOI=10.1038/nature11003
    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature 483:603-607(2012)

    PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
    Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
    Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
    Cancer Discov. 2:172-189(2012)

    PubMed=23151021; DOI=10.1186/1471-2164-13-619
    Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
    Molecular characterisation of cell line models for triple-negative breast cancers.
    BMC Genomics 13:619.1-619.14(2012)

    PubMed=23601657; DOI=10.1186/bcr3415
    Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
    miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
    Breast Cancer Res. 15:R33.1-R33.17(2013)

    PubMed=23671654; DOI=10.1371/journal.pone.0063056
    Lu Y.-H., Soong T.D., Elemento O.
    A novel approach for characterizing microsatellite instability in cancer cells.
    PLoS ONE 8:E63056-E63056(2013)

    PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
    Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
    Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
    Cancer Cell 24:450-465(2013)

    PubMed=24162158; DOI=10.1007/s10549-013-2743-3
    Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
    Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
    Breast Cancer Res. Treat. 142:237-255(2013)

    PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
    Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
    Modeling precision treatment of breast cancer.
    Genome Biol. 14:R110.1-R110.14(2013)

    PubMed=24389870; DOI=10.1038/srep03576
    Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.
    More than apples and oranges -- detecting cancer with a fruit fly's antenna.
    Sci. Rep. 4:3576-3576(2014)

    PubMed=24456987; DOI=10.1186/1755-8166-7-8
    Rondon-Lagos M., Verdun Di Cantogno L., Marchio C., Rangel N., Payan-Gomez C., Gugliotta P., Botta C., Bussolati G., Ramirez-Clavijo S.R., Pasini B., Sapino A.
    Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.
    Mol. Cytogenet. 7:8.1-8.14(2014)

    PubMed=25960936; DOI=10.4161/21624011.2014.954893
    Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
    A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
    OncoImmunology 3:e954893.1-e954893.12(2014)

    PubMed=25984343; DOI=10.1038/sdata.2014.35
    Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
    Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
    Sci. Data 1:140035-140035(2014)

    PubMed=25485619; DOI=10.1038/nbt.3080
    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
    A comprehensive transcriptional portrait of human cancer cell lines.
    Nat. Biotechnol. 33:306-312(2015)

    PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050
    Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
    The proteomic landscape of triple-negative breast cancer.
    Cell Rep. 11:630-644(2015)

    PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
    Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
    Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
    J. Chromatogr. B 1000:95-104(2015)

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5
    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
    Genome Med. 7:118.1-118.7(2015)

    PubMed=26865974; DOI=10.1186/s13742-016-0113-x
    Ciotlos S., Mao Q., Zhang R.Y., Li Z.-Y., Chin R., Gulbahce N., Liu S.J., Drmanac R., Peters B.A.
    Whole genome sequence analysis of BT-474 using Complete Genomics' standard and long fragment read technologies.
    GigaScience 5:8.1-8.17(2016)

    PubMed=27362937; DOI=10.1371/journal.pone.0157290
    Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.
    Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines.
    PLoS ONE 11:E0157290-E0157290(2016)

    PubMed=27378269; DOI=10.1186/s12885-016-2452-5
    Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P., Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
    Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
    BMC Cancer 16:378.1-378.17(2016)

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
    A landscape of pharmacogenomic interactions in cancer.
    Cell 166:740-754(2016)

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
    Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
    Characterization of human cancer cell lines by reverse-phase protein arrays.
    Cancer Cell 31:225-239(2017)

    PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
    Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
    Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
    J. Proteome Res. 16:1391-1400(2017)

    PubMed=28889351; DOI=10.1007/s10549-017-4496-x
    Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res. Treat. 167:289-301(2018)

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
    Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
    Cancer Res. 79:1263-1273(2019)

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3
    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
    Next-generation characterization of the Cancer Cell Line Encyclopedia.
    Nature 569:503-508(2019)

    PubMed=32942617; DOI=10.3390/cancers12092630
    Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.
    HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib attenuates acquired lapatinib-resistance in ER-positive, HER2-overexpressing breast cancer cell line.
    Cancers (Basel) 12:2630.1-2630.16(2020)

    PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
    Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
    Pan-cancer proteomic map of 949 human cell lines.
    Cancer Cell 40:835-849.e8(2022)

    Cross-references
    Cell line databases/resourcesCLO; CLO_0002042
    MCCL; MCC:0000070
    CLDB; cl497
    CLDB; cl498
    CLDB; cl4997
    CCRID; 1101HUM-PUMC000129
    CCRID; 1102HUM-NIFDC00023
    CCRID; 3101HUMTCHu143
    CCRID; 4201HUM-CCTCC00636
    Cell_Model_Passport; SIDM00963
    Cosmic-CLP; 946359
    DepMap; ACH-000927
    DSMZCellDive; ACC-64
    IGRhCellID; BT474
    LINCS_HMS; 50106
    LINCS_LDP; LCL-1308
    TOKU-E; 694
    Anatomy/cell type resourcesBTO; BTO:0001932
    Biological sample resourcesBioSample; SAMN01821539
    BioSample; SAMN01821618
    BioSample; SAMN03473029
    BioSample; SAMN10988308
    BioSamples; SAMEA3516847
    BioSamples; SAMEA3516848
    BioSamples; SAMEA3516849
    Cell line collections (Providers)AddexBio; C0006012/4902
    ATCC; CRL-7913 - Discontinued
    ATCC; HTB-20
    BCRC; 60359
    BCRJ; 0353
    CLS; 300131
    DSMZ; ACC-64
    IBRC; C10140
    ICLC; HTL00008
    KCB; KCB 2011115YJ
    KCLB; 60062
    NCBI_Iran; C435
    Chemistry resourcesChEMBL-Cells; CHEMBL3307636
    ChEMBL-Targets; CHEMBL614529
    GDSC; 946359
    PharmacoDB; BT474_109_2019
    PubChem_Cell_line; CVCL_0179
    Encyclopedic resourcesWikidata; Q54798460
    Experimental variables resourcesEFO; EFO_0001093
    Gene expression databasesArrayExpress; E-MTAB-38
    ArrayExpress; E-MTAB-2706
    ArrayExpress; E-MTAB-2770
    ArrayExpress; E-MTAB-3610
    ArrayExpress; E-TABM-157
    ArrayExpress; E-TABM-244
    GEO; GSM1716
    GEO; GSM1725
    GEO; GSM69198
    GEO; GSM73557
    GEO; GSM73702
    GEO; GSM115110
    GEO; GSM147888
    GEO; GSM147957
    GEO; GSM149981
    GEO; GSM149989
    GEO; GSM149997
    GEO; GSM155210
    GEO; GSM184392
    GEO; GSM184393
    GEO; GSM213707
    GEO; GSM213717
    GEO; GSM213718
    GEO; GSM213719
    GEO; GSM213737
    GEO; GSM213740
    GEO; GSM213743
    GEO; GSM213745
    GEO; GSM217615
    GEO; GSM274657
    GEO; GSM276780
    GEO; GSM320173
    GEO; GSM344341
    GEO; GSM344391
    GEO; GSM350504
    GEO; GSM388211
    GEO; GSM421861
    GEO; GSM533397
    GEO; GSM533412
    GEO; GSM590105
    GEO; GSM679677
    GEO; GSM679678
    GEO; GSM679679
    GEO; GSM679680
    GEO; GSM679681
    GEO; GSM679682
    GEO; GSM679683
    GEO; GSM679684
    GEO; GSM679685
    GEO; GSM679686
    GEO; GSM679687
    GEO; GSM679688
    GEO; GSM679689
    GEO; GSM679690
    GEO; GSM679691
    GEO; GSM783958
    GEO; GSM799168
    GEO; GSM799169
    GEO; GSM799170
    GEO; GSM799171
    GEO; GSM799172
    GEO; GSM799173
    GEO; GSM847198
    GEO; GSM847453
    GEO; GSM843476
    GEO; GSM886892
    GEO; GSM887957
    GEO; GSM903063
    GEO; GSM903064
    GEO; GSM903065
    GEO; GSM903066
    GEO; GSM903067
    GEO; GSM903068
    GEO; GSM903069
    GEO; GSM967821
    GEO; GSM1008891
    GEO; GSM1053692
    GEO; GSM1172941
    GEO; GSM1172853
    GEO; GSM1214587
    GEO; GSM1238128
    GEO; GSM1264068
    GEO; GSM1264073
    GEO; GSM1264110
    GEO; GSM1264115
    GEO; GSM1374408
    GEO; GSM1374409
    GEO; GSM1374410
    GEO; GSM1401649
    GEO; GSM1669630
    GEO; GSM2176271
    GEO; GSM2176272
    Polymorphism and mutation databasesCosmic; 687464
    Cosmic; 871138
    Cosmic; 904351
    Cosmic; 923058
    Cosmic; 934520
    Cosmic; 946359
    Cosmic; 970088
    Cosmic; 979721
    Cosmic; 1000122
    Cosmic; 1017168
    Cosmic; 1018460
    Cosmic; 1046934
    Cosmic; 1047699
    Cosmic; 1071903
    Cosmic; 1129654
    Cosmic; 1136353
    Cosmic; 1176605
    Cosmic; 1287890
    Cosmic; 1289383
    Cosmic; 1308996
    Cosmic; 1434947
    Cosmic; 1523771
    Cosmic; 1603191
    Cosmic; 1609475
    Cosmic; 1945863
    Cosmic; 2165003
    Cosmic; 2301523
    Cosmic; 2318376
    Cosmic; 2361356
    IARC_TP53; 4
    LiGeA; CCLE_516
    Progenetix; CVCL_0179
    Proteomic databasesPRIDE; PXD002281
    PRIDE; PXD002635
    PRIDE; PXD004357
    PRIDE; PXD005390
    PRIDE; PXD008222
    PRIDE; PXD030304
    Sequence databasesEGA; EGAS00001000610
    EGA; EGAS00001000978
    EGA; EGAS00001002554
    Entry history
    Entry creation04-Apr-2012
    Last entry update29-Jun-2023
    Version number43


    更多>>相关产品

    总部地址:北京市怀柔区渤海镇怀沙路536号

    关注杏鑫
    在线咨询
    在线客服
    电话咨询
    微信客服
    返回顶部
    杏鑫娱乐专业提供:杏鑫娱乐杏鑫👨🏻‍🎨、杏鑫平台等服务,提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等,界面美观优质完美,安全稳定,服务一流🚶‍➡️,杏鑫娱乐欢迎您。